Suvannasankha, A., Bahlis, N. J., Trudel, S., Weisel, K., Koenecke, C., Oriol, A., . . . Nooka, A. K. (2024). Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Citación estilo ChicagoSuvannasankha, Attaya|||0000-0001-9445-8781, et al. Safety and Efficacy of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed or Refractory Multiple Myeloma. 2024.
Cita MLASuvannasankha, Attaya|||0000-0001-9445-8781, et al. Safety and Efficacy of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed or Refractory Multiple Myeloma. 2024.
Precaución: Estas citas no son 100% exactas.